UNSPSC 51412702: Alteplase

This classification denotes a differentiation inducer with the molecular formula C2569H3894N746O781S40, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1RXS4UE564, more generally known as alteplase. European Medicines Agency schedules alteplase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05378MIG. The term ALTEPLASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.

ALTEPLASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule alteplase under HS 35079090 and SITC 51691. As of Q4 2014, ALTEPLASE remains the US FDA Preferred Term for this commodity. Alteplase bears US NLM identifiers UMLS ID C0032143 and NCI Concept Code C39607. SMILES: none.

UNSPSC 51412702 Alteplase, a Commodity code, covers emergency pharmaceutical supplies that state and local governments procure through emergency medical services and public health programs. State and local procurement under this code focuses on acquiring specific medications used in acute clinical settings — particularly emergency life support drugs including alteplase and related thrombolytics, vasopressors, antiarrhythmics, and other critical-care injectables. Issuing bodies include municipal fire and rescue departments (as primary end-users), state health agencies managing pharmacy benefit programs, and multi-state cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The City of Tampa's Purchasing Department represents the direct municipal buyer model, while the Texas Health and Human Services Commission and Minnesota's multi-state cooperative purchasing vehicle (MMCAP) represent state-level and regional aggregation models. Procurement takes the form of sealed competitive bidding (IFB) for single-jurisdiction emergency responder supply, exploratory RFI activity for statewide direct-to-manufacturer contracting, and multi-award RFP vehicles for cooperative purchasing across member states and localities.

Geographic activity spans at least Florida, Texas, Minnesota, and Oregon, with the most recent formal solicitation activity driven by municipal emergency services in Florida and multi-state cooperative purchasing. The City of Tampa issued IFB 26P00188 (posted April 24, 2026, response due April 8, 2026) for Advanced Life Support Medications including epinephrine, adenosine, labetalol, and diltiazem — a $40,000 estimated contract with a one-year term and renewal options, sheltered under Small Local Business Enterprise (SLBE) designation with a 5 percent bid discount. Minnesota's MMCAP issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), requiring cGMP and DSCSA compliance and offering a two-year initial term. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) sought vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO channels, signaling state-level interest in supply-chain alternatives that may reshape procurement patterns in coming formal solicitations.